Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Alpha Cognition Inc. (ACOGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5464+0.0554 (+11.28%)
At close: 03:48PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

    NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3nbZJuOThe company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accepting 1x1 manag

  • Zacks Small Cap Research

    ACOGF: Resolving to Move Ahead

    By John Vandermosten, CFA OTC:ACOGF READ THE FULL ACOGF RESEARCH REPORT Bioavailability and Bioequivalence Study Results Alpha Cognition, Inc. (OTC:ACOGF) provided topline results from its bioavailability and bioequivalence (BABE) study in a June 22 nd press release which was followed by a conference call providing additional detail along with a presentation summarizing key data. Results showed

  • Business Wire

    Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease

    VANCOUVER, British Columbia, June 22, 2022--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

Advertisement
Advertisement